

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

KVK-TECH, INC.,

Petitioner,

v.

SHIRE LLC,

Patent Owner.

Case IPR2018-00290
US Patent No. 8,846,100

DECLARATION OF SARA ROSENBAUM, Ph.D.

SHIRE EX. 2002
KVK v. SHIRE
IPR2018-00290

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. EXPERIENCE AND QUALIFICATIONS.....	1
A. Professional Background.....	1
B. Materials Considered for This Declaration	2
III. LEGAL PRINCIPLES.....	4
IV. THE PERSON OF ORDINARY SKILL IN THE ART	6
V. THE ‘100 PATENT CLAIMS ARE DIRECTED TO A THREE- COMPONENT (IR-DPR-SR) AMPHETAMINE DOSAGE SYSTEM WITH SPECIFIC PHARMACOKINETICS AND WITHOUT A FOOD EFFECT	7
A. Amphetamines.....	8
B. Drug Release from an Oral Dosage Form.....	8
a. The GI Tract Is a Complex Environment	9
b. The ‘100 Patent Dosage System Combines Three Different Types of Amphetamine Delivery - IR-DPR-SR	11
C. Pharmacokinetics, Pharmacodynamics, and the Unpredictability of In Vivo from In Vitro and Vice Versa.....	13
a. Pharmacokinetics	14
b. Pharmacodynamics	24
VII. THE ‘100 PATENT PK CLAIMS AND FOOD EFFECT CLAIM	25
VIII. THE PK CLAIMS AND THE FOOD EFFECT CLAIM ARE NOT ANTICIPATED BY BURNSIDE; NOR ARE THEY OBVIOUS OVER BURNSIDE OR ADDERALL XR IN VIEW OF BURNSIDE.....	27
A. The PK Claims Are Not Anticipated	27
B. The Food Effect Claim Is Not Anticipated	29
C. The PK Claims Are Not Obvious over Burnside Alone or ADDERALL XR in view of Burnside	32

TABLE OF CONTENTS
(continued)

	Page
D. THE FOOD EFFECT CLAIM (CLAIM 21) IS NOT OBVIOUS OVER BURNSIDE OR ADDERALL XR IN VIEW OF BURNSIDE	46
APPENDIX A CURRICULUM VITAE	1

DECLARATION OF SARA ROSENBAUM, Ph.D.

I, Sara Rosenbaum, Ph.D., do hereby declare and say as follows:

I. INTRODUCTION

1. I am a citizen of the United States of America and am more than twenty-one (21) years of age. I have been retained by counsel for Patent Owner Shire LLC as an expert in pharmacokinetics to address topics relevant to the subject matter of *KVK-Tech, Inc. v. Shire LLC*, IPR2018-00290, involving the claims of U.S. Patent No. 8,846,100 (the “100 patent”). EX. 1001. I am being compensated at my usual rate for consultation on patent matters, and I am being provided with, or reimbursed for, my expenses. My compensation is in no way dependent on the outcome of this case.

II. EXPERIENCE AND QUALIFICATIONS**A. Professional Background**

2. I am a tenured Professor of Pharmacokinetics in the Department of Biomedical and Pharmaceutical Sciences at the University of Rhode Island College of Pharmacy. I am also an Adjunct Professor of Molecular Pharmacology, Physiology, and Biotechnology at Brown University. I received my Ph.D. (1980) in Pharmacology from Liverpool University. I have taught courses in biopharmaceutics, pharmacokinetics, and pharmacodynamics. I have published more than 40 books and peer-reviewed publications in the field, and have

presented at conferences around the world. I have been Editor-in-Chief and Editor Emeritus of *Clinical Research and Regulatory Affairs* and am a reviewer for *Annals of Clinical Pharmacology* and *Clinical Pharmacokinetics*. Over the course of my career, I have more than three decades of experience in the study of pharmacokinetics.

3. My *curriculum vitae* is attached as Appendix A.

B. Materials Considered for This Declaration

4. In making this Declaration, I relied on over three decades of experience in pharmaceutical studies and have studied and considered: (a) the ‘100 patent (EX1001) and its file history (EX1005); (b) KVK’s Petition and Exhibits in this IPR (EX1001-1042), including the declarations of its experts (EX1004 and EX1006) and its grounds for this IPR (EX1002, EX1003, EX1031, EX1015-1018); (c) KVK’s Petition and Exhibits in related IPR2018-00293; and (d) each of the documents I cite in the body of this Declaration. This includes U.S. Patent 9,173,857 (“the ‘857 patent”), which is EX1001 in the related IPR, and its file history (EX1030 here). I am also submitting a Declaration in IPR2018-00293.

5. I understand that this is an *inter partes* review (“IPR”) proceeding conducted before the Patent Trial and Appeal Board (“Board”) of the U.S. Patent and Trademark Office (“USPTO”) to determine if claims 1-31 of the ‘100 patent (the challenged claims) should be cancelled as unpatentable, in view of certain

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.